Predicting response to proton pump inhibitor (PPI) therapy in patients with laryngeal symptoms is challenging. The Restech Dx-pH probe is a transnasal catheter that measures oropharyngeal pH. In this study, we aimed to investigate the prognostic potential of oropharyngeal pH monitoring to predict responsiveness to PPI therapy in patients with laryngeal symptoms.
INTRODUCTION
Discerning whether patients with laryngeal symptoms will respond to proton pump inhibitor (PPI) therapy is clinically challenging. Although chronic laryngitis due to gastroesophageal refl ux, referred to as laryngopharyngeal refl ux (LPR), is an established extraesophageal refl ux syndrome, there exists signifi cant controversy about the causative role of refl ux and the clinical algorithm for LPR ( 1, 2 ) . Current methods to detect LPR and predict response to treatment are of limited utility ( 3, 4 ) . Although commonly utilized, laryngoscopy is nonspecifi c, and the refl ux fi nding score, a validated laryngoscopic diagnostic tool to semi-quantify severity of fi ndings, suff ers from poor inter-rater reliability ( 5, 6 ) . Similarly, 24-h dual probe ambulatory pH monitoring lacks sensitivity and specifi city, with concerns over placement variability ( 7 ) . Although an area of interest, outcome studies are lacking for combined pH impedance monitoring, and its clinical signifi cance is currently undefi ned ( 1, 8 ) . In the setting of unreliable diagnostic tests, empiric PPI trials are commonly used to assess for symptom response. However, less than half of patients will respond to PPI therapy, with no signifi cant improvement when compared with placebo (9) (10) (11) . Th e defi ciency of a well-defi ned clinical algorithm for LPR oft en results in overutilization of PPI therapy and diagnostic tests. Th e reported cost of diagnosing and managing extraesophageal refl ux is estimated at $5,000 per patient, and actual cost burden is likely even greater. Th is is a major healthcare issue as LPR is an increasingly diagnosed entity, postulated to comprise up to 50% of laryngeal complaints in an otolaryngology practice alone ( 4, 12 ) .
Th e Restech Dx-pH system (Respiratory Technology Corporation, San Diego, CA) is a minimally invasive oropharyngeal pH monitoring device that detects pH in both liquid and aerosolized droplets ( 13, 14 ) . Studies demonstrate that oropharyngeal pH monitoring is highly sensitive in detecting acid refl ux in the posterior oropharynx and more quickly reaches pH equilibrium compared with a standard pH catheter (13) (14) (15) (16) . However, data evaluating the agreement between esophageal pH impedance and oropharyngeal pH are mixed (17) (18) (19) (20) , and, unifi ed normative values for oropharyngeal pH monitoring are lacking, limiting its current role as a diagnostic tool ( 3, (21) (22) (23) . In addition, whether oropharyngeal pH testing is a reliable prognostic tool for medical therapy and surgical outcomes is of great interest ( 15 ) .
Th is study aimed to determine whether oropharyngeal pH moni toring predicts PPI response in patients with laryngeal symptoms. We hypothesized that patients with higher oropharyngeal acid exposure would be more likely to respond to PPI therapy.
METHODS

Setting and subjects
We conducted a prospective observational cohort study at an academic medical center between January 2013 and October 2014. Th e Institutional Review Board approved the study, and a ClinicalTrials.gov record was maintained (ClinicalTrials.gov Identifi er: NCT01755221). Patients between the ages of 18 and 89 years presenting to the otolaryngology clinic for a standard of care evaluation for laryngeal symptoms were recruited to participate. Eligible patients had symptoms classically associated with LPR for greater than 1 month and a total Refl ux Symptom Index (RSI) score ≥13 ( 6 ) . Patients were excluded if PPI use was contraindicated or if they were currently taking a PPI and unable or unwilling to stop the medication for a minimum of 2 weeks before oropharyngeal pH probe placement. Patients were also excluded if they were pregnant, unable to stop anticoagulant use, or unwilling or unable to undergo an oropharyngeal pH assessment.
Study design
Patients received a fl exible fi ber optic video laryngoscopy as part of their standard of care evaluation, and the refl ux fi nding score was collected. Patients completed several self-administered questionnaires to obtain a baseline assessment of LPR symptom severity and duration, gastroesophageal refl ux disease (GERD) symptom frequency, and symptom-specifi c anxiety, discomfort, aff ect, and stress. Th e questionnaire set included the RSI, a validated patientreported laryngeal symptom questionnaire ( 6, 24 ) , GerdQ, a validated instrument for evaluating GERD symptoms ( 25 ) , the visceral sensitivity index, a validated instrument for gastrointestinal symptom-specifi c anxiety ( 26 ) , and the Brief Symptom Inventory-18, a validated psychosocial self-report symptom scale ( 17 ) . In addition, the heartburn vigilance scale, adapted from the validated Pain Vigilance and Awareness Questionnaire, and the Heartburn Catastrophizing Scale, adapted from the pain catastrophizing scale, were used to examine refl ux-specifi c thought and discomfort ( 27, 28 ) . Th e Anxiety Sensitivity Inventory, a validated instrument that assesses beliefs about the social and somatic consequences of anxiety symptoms, and the Discomfort Intolerance Scale, a self-report measure of the ability to tolerate uncomfortable sensations, were used to evaluate gastrointestinal symptomspecifi c anxiety (29) (30) (31) . Patients also completed the Positive and Negative Aff ect Schedule, a valid measure of positive and negative aff ect, and the Perceived Stress Scale-4, a shortened version of the Perceived Stress Scale, a validated measure of global perceived stress in relation to health outcomes (32) (33) (34) (35) .
Patients underwent oropharyngeal pH assessment with the Restech Dx-pH system. Members of the research team prepared the device by calibrating it at pH levels of four and seven according to the manufacturer's instructions. Th e pH probe was placed transnasally with the probe resting one cm below the uvula as recommended by the manufacturer. Patients were instructed to carry out their usual routine while the probe was in place, with the exception of vigorous physical activity. Patients recorded symptom events such as coughing, heartburn, and throat clearing in a written diary and on a wireless transponder they carried with them during the assessment period. Th e next day (24 h later), patients returned to the clinic for probe removal. Studies were excluded if less than 16 h of analyzable data was available. In a blinded manner, physicians analyzed the oropharyngeal pH tracings according to the manufacturer's recommendations.
Aft er probe removal, patients initiated an 8-to 12-week course of omeprazole 40 mg daily, thirty minutes prior to the fi nal meal of the day, per the otolaryngology standard of care practice at our
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institution. At the conclusion of the PPI therapy course, patients returned for a standard of care follow-up visit and completed the aforementioned questionnaire set to obtain a post-PPI therapy assessment of symptom burden.
Defi nitions
Currently, there is no standard defi nition of PPI response for LPR; thus, PPI response was defi ned by separating patients into subgroups based on percent response and post-treatment RSI scores. Non-response was defi ned as post-treatment RSI ≥13; Partial response was defi ned as a post-treatment RSI <13 but a percent change in RSI <50%; and Complete response was defi ned as a post-treatment RSI <13 and a percent change in RSI ≥50%.
Outcomes
Th e primary outcome was the association between PPI response and oropharyngeal pH testing parameters. Oropharyngeal pH tracings were analyzed at pH levels of 4.0, 5.0, 5.5, and 6.0 in the upright position and over the total time period. On the basis of a previous study, which detected a post-supine lag artifact with the soft ware, adjustments were made to calculate corrected time below pH 5.5 in total and upright positions ( 3 ). In addition, composite scores for oropharyngeal pH testing (RYAN scores) were calculated in the upright and supine positions ( 22 ) .
Th e secondary outcomes were the associations between PPI response and psychosocial questionnaire results, including baseline and change (post-pre) results.
Statistical analysis
Th e primary analysis evaluated PPI response as a dependent variable, considering patients in three subgroups: non-responder, partial responder, and complete responder. Diff erences in baseline clinical variables, oropharyngeal pH testing, and questionnaire data were analyzed via χ 2 -analysis for categorical variables and multinomial logistic regression.
In addition, we performed a secondary analysis to assess the relationships between the change in RSI score (post-pre) and baseline clinical variables, oropharyngeal pH testing, and questionnaire data via an ordinary least square (OLS) regression. Hypothetically, the OLS regression may identify associations that were obscured in the categorical primary analysis.
Baseline RSI was used as a covariate in each generalized logit and multiple linear regression model. Each outcome variable was tested in a separate model. As we did not adjust for multiple hypothetical tests, P -values <0.01 were considered signifi cant, and P -values between 0.01 and 0.10 were considered marginally signifi cant. All analyses were conducted using SAS 9.3 (SAS Institute, Cary, NC). Multinomial logistic was run using PROC LOGISTIC with the GLOGIT link function for generalized logit.
RESULTS
Of the 236 patients with suspected LPR screened for the study, 29 did not meet the inclusion criteria and 110 met the exclusion criteria. Of the 97 eligible patients, 42 (43.3%) consented and enrolled. Th e 34 (81%) of the 42 patients who had 16-24 h of analyzable oropharyngeal pH data and completed the appropriate questionnaires aft er PPI therapy were included in the fi nal analysis ( Figure 1 ).
Baseline fi ndings
Twenty-four (71%) patients were female gender with an overall mean age of 45.5±13.3 years and mean body mass index of 27 
Rates of PPI response
Overall, the mean change (post-pre) in RSI score was a decrease in 8.9±9.2 points, and mean percent change in RSI was a reduction by 37.0±39.7%. Seventeen (50%) were non-responders, whereas 5 (15%) met the defi nition for partial response and twelve (35%) for complete response ( Figure 2 ). Baseline clinical variables between these three subgroups did not signifi cantly diff er; however, 88% of non-responders were female, whereas 40% of partial responders and 58% of complete responders were female ( P =0.06). In addition, only two patients were smokers, and both did not respond to PPI therapy ( Table 1 ) .
Pre-treatment variables
Th e pre-treatment RSI score was signifi cantly higher in the nonresponder group ( P< 0.01); as such, pre-RSI was considered a covariate in study analyses. Diff erences in pre-treatment psychosocial questionnaire responses were not signifi cant in primary or secondary analyses.
Oropharyngeal pH testing . Th ere were no signifi cant diff erences in baseline oropharyngeal acid exposure between the three subgroups in primary analysis. Table 2 depicts the data for oropharyangeal pH measurements below pH values of 5.0, 5.5 (corrected), and RYAN scores (corrected); additional pH descriptive data are presented in the Supplementary Table online. In secondary (OLS) analysis, we noted a trend between lower PPI response and greater total percent time below pH of 5.0 ( P =0.03), upright percent time below pH of 5.0 ( P =0.07), and RYAN supine (corrected; P =0.03); otherwise no signifi cant associations were detected.
Post-treatment variables
Changes in GerdQ were not associated with PPI response. In secondary analysis (OLS regression), PPI response was associated with greater decreases in Anxiety Sensitivity Inventory ( P <0.01), Brief Symptom Inventory-18 ( P <0.01), Negative Aff ect Scale ( P <0.01), and Perceived Stress Scale ( P <0.04); these trends were ESOPHAGUS VOLUME 111 | NOVEMBER 2016
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not signifi cant in the primary analysis (generalized logit model). PPI response was not associated with changes in Discomfort Intolerance Scale, Visceral Sensitivity Index, Heartburn Vigilance Scale, or Heartburn Catastrophizing Scale in both analyses ( Figure 3 ).
DISCUSSION
In this physician-blinded prospective observational cohort study, neither oropharyngeal pH testing nor pre-treatment psychosocial factors predicted laryngeal symptom response to PPI therapy, and 
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RSI scores were associated with PPI non-response, suggesting that severity of initial symptoms is associated with refractoriness to PPI treatment.
Our fi ndings diff er from other studies examining the relationship between oropharyngeal pH testing and PPI response. In a retro spective case-control study of 170 patients with LPR symptoms, Friedman et al. ( 36 ) reported that PPI therapy based on a positive RYAN score compared with empiric PPI therapy resulted in signifi cantly increased symptom response and compliance to therapy; however, in both the control and case groups, the RSI signifi cantly decreased following treatment, with mean post-treatment RSIs <13. A prospective study of 22 patients with LPR symptoms reported a 59% response rate to PPI therapy and described that oropharyngeal pH testing has a 69% sensitivity and a 100% specifi city for predicting PPI response. However, response was defi ned as at least a fi ve-point decrease in RSI; derivation of this fi ve-point decrease threshold is unclear. Furthermore, the statistical model did not control for pre-RSI or examine the percentage our results do not support the use of these as clinical surrogates for predicting response to PPI therapy.
Contrary to our hypothesis that greater acid exposure would predict PPI response, our secondary analysis (OLS regression) suggested that a higher oropharyngeal acid burden (defi ned as less than pH level of 5.0) exists for PPI non-responders. Although not found in primary analysis when comparing responder types, this phenomenon is thought provoking, suggesting that those with higher acid exposure between pH of 4.0 and 5.0 are increasingly refractory to the therapeutic benefi ts of PPI therapy. Perhaps this refl ects that the laryngopharynx is most sensitive to exposure below pH levels of 5.0 and that PPIs are less eff ective in reducing pH below this level. As seen in our prior study, an oropharyngeal pH level of 5.0 in the context of laryngeal symptoms appears to be most discriminatory, and further work to determine thresholds at this pH level are needed ( 3 ). Despite this relationship, there was an absence of measurable events below a pH level of 5.0 in the majority of PPI non-responders. As expected, higher pre-treatment change in RSI or RSI thresholds ( 37 ) . Th ese studies, including ours, highlight the need for clarifying thresholds and normative values for oropharyngeal pH testing and RSI prior to studying the predictive role of oropharyngeal pH testing. In particular, we previously found that one-third of healthy volunteers manifested abnormal upright RYAN scores, questioning the validity of the RYAN score and urging reexamination of normal and abnormal cutoff values ( 3 ) . In an attempt to circumvent these issues, our study defi ned response based on RSI thresholds and response rates reported in the literature and additionally conducted a secondary analysis to examine associations. Moreover, our analysis assessed percent time of oropharyngeal acid exposure in place of normative thresholds. Th e question of whether GERD is a co-factor in LPR remains unanswered. PPI responders in our study did not have higher initial GerdQ nor heartburn vigilance or heartburn catastrophizing scores than non-responders, suggesting that all patients with laryngeal symptoms who derive benefi t from PPI therapy do not have classic co-morbid GERD. Factors beyond acidic gastroesophageal refl ux are known to contribute to laryngeal pathology. For instance, allergen exposure is related to supraglottic eosinophilia ( 38 ) . Work in esophageal eosinophilia suggests that the therapeutic role of PPIs may extend beyond an antacid mechanism and involve anti-infl ammatory properties; future studies should examine the association between laryngeal eosinophilia and PPI response ( 39 ) . In addition, tobacco is associated with elevated subglottic mucin, and smokers are at risk of developing chronic laryngeal disease and cancer outside of their acid exposure ( 38 ) . Another theory is that acidic refl ux is not the primary driver of laryngeal symptoms. Higher salivary pepsin concentrations have been detected in patients with laryngeal complaints without evidence of higher oropharyngeal acid exposure ( 3 ). Pepsin is postulated to be a potential biomarker of GERD ( 40 ) , and it is possible that either a non-acidic or a higher volume of refl uxate drives symptoms or that 24-h monitoring may not capture the original insult.
Th e role of psychosocial factors in the presentation of laryngeal symptoms is an area of interest. In our study, PPI response paralleled the reduction in psychosocial scores of anxiety, stress, and negative aff ect; however, the psychosocial scores did not predict PPI response. Laryngeal hypersensitivity may have a role in symptom recognition in laryngeal irritation, similar to the concept of esophageal hypersensitivity in patients with persistent troublesome GERD symptoms ( 41, 42 ) . At the same time, it is possible that patients enrolled in a clinical trial may be more likely to feel better with regard to health-related outcomes, translating to improvements in psychosocial questionnaire results. Although this chicken and egg phenomenon is unclear, our results do support the interplay between psychosocial factors and symptom generation. Th ese considerations reiterate the importance of tailoring management to symptom genesis, as PPI therapy as a primary treatment may not be indicated, and therapeutic strategies for certain subgroups should include cognitive behavioral therapy and neuromodulation.
Although limited by a small sample size, these results suggest that oropharyngeal pH testing is unlikely to have suffi cient specifi city to replace empiric PPI therapy in the initial treatment algorithm for patients with suspected LPR. Furthermore, this study was not designed to measure the actual eff ect of PPI therapy, as on-treatment pH measurements were not performed, and this question would be best evaluated in a larger randomized controlled manner with a placebo arm. Our patients also had low baseline GerdQ scores, and GERD symptom response to PPI therapy was thus diffi cult to interpret. Finally, we examined several oropharyngeal pH parameters and psychosocial factors, which introduces the possibility of familywise error. Although none of the pH parameters were strongly statistically signifi cant or would stand up to familywise adjustment, P -values should be interpreted cautiously.
In conclusion, our results do not support the use of oropharyngeal pH testing or psychosocial questionnaires to predict symptom response to PPI therapy. Th is study importantly cautions against clinical reliance on oropharyngeal pH monitoring as a prognostic tool in suspected LPR. Unexpectedly, our study signals that the degree of oropharyngeal acid exposure may be inversely related to PPI response; as such, thresholds and the relationship between acid exposure and PPI response need to be clarifi ed before utilizing this technology to guide management decisions of long-term PPI therapy or antirefl ux procedures. In addition, further work is needed to understand the mechanisms involved in laryngeal symptom genesis. Th is study suggests a relationship between laryngeal symptoms and psychosocial factors, providing groundwork for future studies to incorporate these therapeutic targets into clinical algorithms.
